Financial
FY2025 revenue RMB 33.28bn (-9.4%); net margin 25.4%; net income RMB 8.45bn.
Net profit fell 30.3%; operating profit not stated in summary.
Mindray
HQ China · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: 300760.SZ
FY2025 revenue RMB 33.28bn (-9.4%); net margin 25.4%; net income RMB 8.45bn.
Net profit fell 30.3%; operating profit not stated in summary.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | CN¥33.3bn | -9.4% | — | CN¥8.5bn | Shenzhen Mindray Bio-Medical Electronics |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.